Hematology

EHA Abstracts Preview Potential for Eculizumab Contenders

June 21st 2022

By Skylar Jeremias

Abstracts from the 2022 European Hematology Association (EHA) Congress presented positive data for 2 biosimilar candidates referencing Soliris (eculizumab).

Blood Clot Prevention Biosimilars Achieve Reimbursement in British Columbia

March 24th 2022

By Skylar Jeremias

Podcast

Three biosimilars used for blood clot prevention secure public reimbursement status in British Columbia, one of several Canadian provinces that has a biosimilar switching program.

SB12 Eculizumab Biosimilar Candidate Demonstrates PK, PD Equivalence in Phase 1 Trial

December 18th 2021

By Tony Hagen

Article

In a pharmacokinetic (PK) and pharmacodynamic (PD) trial in healthy participants, Samsung Bioepis' SB12 eculizumab biosimilar candidate demonstrated equivalence to Soliris, the reference product.

Xbrane Seeks to Bring Keytruda and Darzalex Biosimilars to Market

December 15th 2021

By Tony Hagen

Article

Xbrane Biopharma of Stockholm, Sweden, said its next biosimilar candidates will target the demand for oncology and hematology therapeutics.

EHA25 Virtual Roundup

June 18th 2020

By Skylar Jeremias

Video

Here is a summary of our coverage from EHA25 Virtual, the annual meeting for the European Hematology Association (EHA).

Data on Complement Inhibitors and Proposed Biosimilars Feature at ASH

December 10th 2019

By Kelly Davio

Article

During this week’s 61st meeting of the American Society of Hematology (ASH), researchers reported on eculizumab, a prospective biosimilar, and the long-acting ravulizumab.

Amgen's Eculizumab Biosimilar, ABP 959, Shows PK, PD Bioequivalence to Soliris

June 18th 2019

By The Center for Biosimilars Staff

Article

Amgen is developing a biosimilar of the drug, ABP 959, and during last week’s 24th Congress of the European Hematology Association, held from June 13-16 in Amsterdam, the Netherlands, researchers reported on findings from a phase 1 trial of the proposed product.

Updated ASCO and ASH Guidelines on Managing Anemia Support Safety, Efficacy of Biosimilar ESAs

April 16th 2019

By The Center for Biosimilars Staff

Article

The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) first published their guidelines on erythropoiesis-stimulating agents (ESAs) in cancer care in 2002, with updates in 2007 and 2010, and the new update is the first to address biosimilar epoetin alfa.

Biosimilar Hematology Roundup: December 2018

December 28th 2018

By Kelly Davio

Article

On the heels of the FDA approval of Celltrion’s rituximab biosimilar Truxima in November 2018, December saw the publication of a variety of new data on biosimilars used in hematology.

More Data Underscore the Safety and Efficacy of CT-P10 in Hematological Conditions

December 4th 2018

By Kelly Davio

Article

Celltrion’s CT-P10, a biosimilar rituximab that was FDA approved under the brand name Truxima in November 2018, is already in wide use for a host of indications in many regulatory territories. During this week’s 60th Annual Meeting and Exposition of the American Society of Hematology in San Diego, California, multiple research teams are reporting data that underscore the safety and efficacy of CT-P10 in hematological conditions.